NASDAQ:ORGO
Organogenesis Holdings Inc. Class A Stock News
$2.77
+0.0300 (+1.09%)
At Close: May 20, 2024
5 Red-Hot Stocks Trading Under $10 With Massive Upside Potential
06:15am, Saturday, 16'th Jan 2021
While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Why Organogenesis Holdings Stock Is Soaring Today
12:52pm, Thursday, 14'th Jan 2021
The company announced its preliminary fourth-quarter financial results.
Organogenesis Enrolls First Patient in Pivotal Phase 3 Clinical Trial of RMAT-Designated ReNu® for Knee Osteoarthritis
07:00am, Thursday, 14'th Jan 2021
CANTON, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of pr
Stocks making the biggest moves after the bell: Nordstrom, Ethan Allen & more
04:56pm, Wednesday, 13'th Jan 2021
These are the stocks posting the largest moves after the bell on Wednesday.
Organogenesis Holdings Inc. Reports Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020
04:05pm, Wednesday, 13'th Jan 2021
CANTON, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p
Organogenesis ReNu® Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Osteoarthritis of the Knee
09:01am, Monday, 11'th Jan 2021
FDA Determines ReNu Preliminary Clinical Evidence Indicates Potential to Address Unmet Medical Needs for the Management of Symptoms Associated with Knee Osteoarthritis
Why Nasdaq Can Win Again in 2021 After the Best Year Since 2009
08:18pm, Tuesday, 05'th Jan 2021
New strain of coronavirus, growing demand for digitization and past record indicate that the Nasdaq can win in 2021 too after its best year since 2009.
Organogenesis Holdings Inc. to Participate in the ICR Conference 2021
04:05pm, Tuesday, 05'th Jan 2021
CANTON, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p
Organogenesis: Revenue Generating Regenerative Medicines Company Looking Interesting
09:30am, Friday, 20'th Nov 2020
Organogenesis is a revenue-generating regenerative medicines company with a long pipeline. The company has decades of operating history behind it.
Organogenesis Holdings Inc. Announces Pricing of Public Offering of Class A Common Stock
12:45am, Friday, 13'th Nov 2020
CANTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p
Organogenesis Holdings Inc. Announces Proposed Public Offering of Class A Common Stock
05:40pm, Tuesday, 10'th Nov 2020
CANTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p
Organogenesis Holdings Inc. (ORGO) CEO Gary Gillheeney on Q3 2020 Results - Earnings Call Transcript
10:19pm, Monday, 09'th Nov 2020
Organogenesis Holdings Inc. (ORGO) CEO Gary Gillheeney on Q3 2020 Results - Earnings Call Transcript
Organogenesis Holdings Inc. Reports Third Quarter and Nine Months 2020 Financial Results
04:05pm, Monday, 09'th Nov 2020
CANTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p
Latest Wound Care Research from Organogenesis Highlighted at SAWC Fall 2020 Virtual Meeting
04:30pm, Monday, 02'nd Nov 2020
CANTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of pr
The Global Tissue Scaffolds Market will grow by $ 1.38 bn during 2020-2024
